Acadia Pharmaceuticals: Bullish On Nuplazid And Daybue Driven Growth In CNS Treatments


  • ACADIA Pharmaceuticals is a biopharmaceutical company specializing in CNS disorder treatments, with two successful FDA-approved commercial products, Nuplazid and Daybue.
  • Nuplazid, indicated for Parkinson’s disease psychosis, generates over $300 million in yearly cash flow, while Daybue, approved for Rett syndrome, had a successful launch.
  • ACAD has a promising pipeline of drug candidates, including ACP-101 for Prader-Willi syndrome and ACP-204 for Alzheimer’s disease psychosis, which could create additional revenue verticals.
  • The company is developing ACP-101 for Prader-Willi syndrome and ACP-204 for Alzheimer’s disease psychosis.
  • ACAD’s strong pipeline and solid cash flow support its valuation, making it a compelling investment alternative in biotech.

Neuronas de disparo

koto_feja/E+ via Getty Images

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a biopharmaceutical company specializing in developing treatments for central nervous system [CNS] conditions. The company has two successful FDA-approved commercial franchises, Nuplazid (pimavanserin), approved in 2016 for Parkinson’s disease psychosis, and Daybue (trofinetide), approved in March 2023 for

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Leave a Reply

Your email address will not be published. Required fields are marked *